A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...
Researchers at the Cornell University College of Veterinary Medicine (CVM) are a step closer to finding the fountain of youth ...
Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...
Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in ...
A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
Background Eosinophilic oesophagitis (EoE) is a chronic allergic disease characterised by oesophageal epithelial remodelling, barrier dysfunction and inflammation. The transcription factor forkhead ...
Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in ...
Komal Jhaveri - Breast Medical Oncologist and Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center, New York, ...
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
For more details about SABCS please visit: https://www.sabcs.org/.
A new mouse study shows high-dose aluminum adjuvant Imject Alum can induce liver fibrosis via inflammasome activation, ...
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback